Landscapes / Targets
PDE
3 drugs act on PDE, in 11 active trials · Any stage · updated 18 Nov 2026
FollowEvery change as it happens, and a Monday email
Drugs3
| Drug | How it works | Company | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
PDE3/PDE4 inhibitor (inhaled) |
Merck & Co. +1 · Public MRK |
Approved | 1 Mar 2027Phase 2 trial completes | ||
| Next date | 1 Mar 2027 · Phase 2 trial completes | ||||
| Also tested for | Pulmonary Disease, Chronic Obstructive, COPD, Non-cystic Fibrosis Bronchiectasis and 1 more | ||||
| Open drug page | |||||
PDE4B-preferring PDE4 inhibitor |
Boehringer Ingelheim · Private |
Approved | 15 Apr 2027Phase 3 trial completes | ||
| Next date | 15 Apr 2027 · Phase 3 trial completes | ||||
| Also tested for | Interstitial Lung Diseases, Idiopathic Pulmonary Fibrosis and 7 more | ||||
| Open drug page | |||||
— |
Phase 2/3 | Apr 2027Phase 2/3 trial completes | |||
| Next date | Apr 2027 · Phase 2/3 trial completes | ||||
| Also tested for | Amyotrophic Lateral Sclerosis | ||||
| Open drug page | |||||
No drugs match “”.
About this list
- Checked
- 3 of 3 drugs. How we check
- Matches
- The mechanism of checked drugs, and drug names, so a drug not checked yet may be missing.
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · openFDA updated 17 Nov 2026